The abstract is read at the publisher; the summary is JClub's.
Exogenous acetate suppresses esophageal squamous cell carcinoma tumorigenesis by ACSS2-dependent H2A.Z acetylation, linked to ATM activation and reduced proliferation in vitro and in vivo.
- Why it matters: The epigenome–metabolome link involving acetate and ACSS2 is established in other cancers, but its role in ESCC and its therapeutic implications remain unclear.
- What they did: Human ESCC tissues show decreased acetate and ACSS2, with low ACSS2 linked to poor prognosis; acetate treatment was tested in vitro and in vivo, alongside ACSS2 knockdown and H2A.Z acetylation-site mutation.
- The result: Acetate robustly inhibits ESCC proliferation, and this effect is abrogated by mutating the three H2A.Z acetylation sites or by ACSS2 knockdown, supporting an acetate–ACSS2–H2A.Zac–ATM tumor-suppressive axis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.